Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.98
Zymeworks Inc. incurred term loan of $250.0 million with Royalty Pharma Development Funding, LLC at fixed rate maturing December 31, 2042.
- Instrument
- term loan
- Principal
- $250.0 million
- Counterparty
- Royalty Pharma Development Funding, LLC
- Rate
- fixed rate
- Maturity
- December 31, 2042
- Event
- incurrence
Exact text from the filing
Following the sale and transfer of the Royalty Interest, the Subsidiary entered into a Loan Agreement (the “ Loan Agreement ”), dated March 2, 2026, with Royalty Pharma as administrative agent and lender (in the capacity as lender under the Loan Agreement, the “ Lender ” and together with such other lenders party to the Loan Agreement from time to time the “ Lenders ”), pursuant to which the Lenders made a term loan to the Subsidiary (the “ Loan ”) in an aggregate principal amount of $250.0 million (the “ Loan Amount ”), that bears interest at a fixed rate and matures on December 31, 2042 (the “ Maturity Date ”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Zymeworks Inc. entered into Sale Agreement with Royalty Pharma Development Funding, LLC valued at $250.0 million (effective 2026-03-02).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Royalty Pharma Development Funding, LLC
- Value
- $250.0 million
- Effective
- 2026-03-02
Exact text from the filing
On March 2, 2026, Zymeworks BC Inc. (“ Zymeworks BC ”), a subsidiary of Zymeworks Inc. (the “ Company ”), entered into a sale agreement (the “ Sale Agreement ”) with Zymeworks Royalty Limited Partnership (the “ Subsidiary ”), a special purpose entity newly formed by Zymeworks BC and by its general partner Zymeworks General Partner ULC (“ Zymeworks GP ”), the Company solely for the purpose of certain indemnification provisions thereunder, and Royalty Pharma Development Funding, LLC (“ Royalty Pharma ”) as administrative agent.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Zymeworks Inc. entered into Loan Agreement with Royalty Pharma Development Funding, LLC valued at $250.0 million (effective 2026-03-02).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Royalty Pharma Development Funding, LLC
- Value
- $250.0 million
- Effective
- 2026-03-02
Exact text from the filing
Following the sale and transfer of the Royalty Interest, the Subsidiary entered into a Loan Agreement (the “ Loan Agreement ”), dated March 2, 2026, with Royalty Pharma as administrative agent and lender (in the capacity as lender under the Loan Agreement, the “ Lender ” and together with such other lenders party to the Loan Agreement from time to time the “ Lenders ”), pursuant to which the Lenders made a term loan to the Subsidiary (the “ Loan ”) in an aggregate principal amount of $250.0 million (the “ Loan Amount ”), that bears interest at a fixed rate and matures on December 31, 2042 (the “ Maturity Date ”).
View on SEC.gov